{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Doxycycline as an Adjunct to Endovascular Aneurysm Repair"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "This double-blind, placebo-controlled trial randomised patients undergoing EVAR"
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised patients undergoing EVAR to doxycycline (100 mg twice daily) or placebo for 6 months"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study assesses the impact of doxycycline, an MMP inhibitor, on EVAR outcomes."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was plasma MMP-9 levels at 6 months"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was achieved using [randomisation method] with allocation concealment via [allocation concealment method]"
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding encompassed patients, clinicians, and outcome assessors."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 44 patients were randomised: 20 to doxycycline and 24 to placebo."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Intention-to-treat analysis revealed a significant reduction"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "a significant reduction in plasma MMP-9 in the doxycycline group at 6 months (\u221216.4\u00b120.7%, P<0.05)"
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: [registration number]."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: [source of funding]."
      }
    },
    "total_score": 18,
    "max_score": 25
  },
  "model": "gpt-4o"
}